Free Trial

Eledon Pharmaceuticals (ELDN) Competitors

Eledon Pharmaceuticals logo
$3.11 +0.03 (+0.97%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$3.26 +0.15 (+4.69%)
As of 07/7/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELDN vs. REPL, PHAR, SANA, NUVB, AVBP, TRVI, ANAB, IMTX, DAWN, and MRVI

Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Replimune Group (REPL), Pharming Group (PHAR), Sana Biotechnology (SANA), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

Eledon Pharmaceuticals vs. Its Competitors

Eledon Pharmaceuticals (NASDAQ:ELDN) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Eledon Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Replimune Group's return on equity of -57.98% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -79.54% -41.62%
Replimune Group N/A -57.98%-45.21%

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eledon Pharmaceuticals currently has a consensus target price of $9.00, suggesting a potential upside of 189.39%. Replimune Group has a consensus target price of $20.83, suggesting a potential upside of 115.89%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Replimune Group
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

In the previous week, Replimune Group had 6 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Replimune Group and 0 mentions for Eledon Pharmaceuticals. Replimune Group's average media sentiment score of 0.44 beat Eledon Pharmaceuticals' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media.

Company Overall Sentiment
Eledon Pharmaceuticals Neutral
Replimune Group Neutral

Replimune Group is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$36.18M-$2.10-1.48
Replimune GroupN/AN/A-$247.30M-$3.07-3.14

Summary

Replimune Group beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELDN vs. The Competition

MetricEledon PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$184.44M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.07%
P/E Ratio-1.4820.3027.1920.03
Price / SalesN/A249.79413.88108.83
Price / CashN/A41.7026.2128.59
Price / Book1.577.397.925.55
Net Income-$36.18M-$55.04M$3.17B$248.49M
7 Day Performance11.47%2.51%1.78%4.87%
1 Month Performance0.97%-0.21%1.26%6.63%
1 Year Performance25.91%3.41%33.31%20.38%

Eledon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELDN
Eledon Pharmaceuticals
2.5332 of 5 stars
$3.11
+1.0%
$9.00
+189.4%
+24.9%$184.44MN/A-1.4810
REPL
Replimune Group
4.1504 of 5 stars
$9.65
+2.7%
$20.83
+115.9%
+19.0%$724.61MN/A-3.14210High Trading Volume
PHAR
Pharming Group
2.7013 of 5 stars
$10.47
-1.0%
$30.00
+186.5%
+28.8%$719.77M$297.20M-52.35280Gap Down
SANA
Sana Biotechnology
2.5452 of 5 stars
$3.10
-2.8%
$9.17
+195.7%
-39.1%$719.27MN/A-3.52380
NUVB
Nuvation Bio
3.5826 of 5 stars
$2.08
-0.5%
$7.17
+244.6%
-31.4%$711.15M$7.87M-0.8960High Trading Volume
AVBP
ArriVent BioPharma
1.7197 of 5 stars
$20.17
-2.9%
$40.00
+98.3%
+8.4%$710.59MN/A-5.3540
TRVI
Trevi Therapeutics
3.2509 of 5 stars
$5.95
flat
$20.88
+250.8%
+130.6%$697.89MN/A-13.2220
ANAB
AnaptysBio
2.2604 of 5 stars
$23.45
-1.3%
$42.38
+80.7%
-5.3%$697.79M$91.28M-4.84100
IMTX
Immatics
2.3921 of 5 stars
$5.53
-3.2%
$14.67
+165.2%
-52.9%$694.05M$168.65M-32.53260Positive News
DAWN
Day One Biopharmaceuticals
1.6934 of 5 stars
$6.63
-2.5%
$30.57
+361.1%
-51.6%$689.27M$131.16M-9.3460Upcoming Earnings
MRVI
Maravai LifeSciences
3.8588 of 5 stars
$2.60
-2.6%
$6.64
+155.3%
-62.8%$679.94M$259.18M-2.28610Positive News

Related Companies and Tools


This page (NASDAQ:ELDN) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners